Email this article 
Hematopoietic stem cell transplantation in juvenile myelomonocytic leukemia: analyse one centre experience and literature review
- Authors: Maschan M.A.1, Khachatryan L.A.1, Skvortsova Y.V.1, Kurnikova E.E.2, Shasheleva D.A.1, Bobrynina V.O.1, Balashov D.N.1, Skorobogatova E.V.1, Baydildina D.D.1, Novichkova G.A.1, Maschan A.A.1
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology and Immunology
- Russian Children Clinical Hospital
- Issue: Vol 6, No 1 (2011)
- Pages: 45-55
- Section: HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Published: 24.02.2011
- URL: https://oncohematology.abvpress.ru/ongm/article/view/105
- DOI: https://doi.org/10.17650/1818-8346-2011-6-1-45-55
- ID: 105
Cite item
Full Text
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy for juvenile myelomonocytic leukemia (JMML). Seventeen patients with JMML received myeloablative conditioning (busulfan-based — 15, treosulfan-based — 2). Donors included 5 matched related siblings, 8 — matched unrelated volunteer or cord blood (2), 4 — mismatched relatives. Primary engraftment was achieved in 75 %. The rate of acute GVHD grade II–IV was 58 %, grade III–IV — 23 %. Chronic GVHD occurred in 33 % of patients. Five JMML relapses occurred. Relapse-free survival is 66 ± 12 %. Four patients died of transplant-related complications. TRM was 28 ± 12 %.
Five patients died of disease progression. Overall survival is 38 ± 13 % with median follow-up of 13 months. A review of most important publications related to HSCT in JMML is provided.
About the authors
M. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Author for correspondence.
Email: mmaschan@yandex.ru
Russian Federation
L. A. Khachatryan
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
Yu. V. Skvortsova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
E. E. Kurnikova
Russian Children Clinical HospitalRussian Federation
D. A. Shasheleva
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
V. O. Bobrynina
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
D. N. Balashov
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
E. V. Skorobogatova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
D. D. Baydildina
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
G. A. Novichkova
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
A. A. Maschan
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Federation
References
Supplementary files
